Evonik Industries supplies RESOMER RG 756 S as a bioresorbable poly(D,L-lactide-co-glycolide) (PLGA) drug delivery grade. The nominal D,L-lactide:glycolide molar ratio is 75:25, the material is supplied as white to off-white granules, and the polymer is an ester-terminated random copolymer. Inherent viscosity, determined as a 0.1% w/v solution in chloroform at 25°C using an Ubbelohde capillary viscometer per DIN EN ISO 1628-1, is controlled within 0.71–1.0 dL/g. Weight-average molecular weight is reported by gel permeation chromatography with polystyrene calibration, typically between 76,000 g/mol and 115,000 g/mol; glass transition temperature measured by differential scanning calorimetry according to ISO 11357-2 falls between 45°C and 50°C. The ester-terminated character reduces the concentration of free carboxylic acid chain ends relative to acid-terminated analogues, which alters water uptake and autocatalytic hydrolysis. The grade is intended for conversion into microspheres, in situ forming depots, and solid implants where release intervals longer than those obtained with 50:50 PLGAs are required.

Specification envelope and batch-release analytics

Release specifications are supplied on the manufacturer certificate of analysis. The comonomer ratio is normally reported as a range around the 75:25 target because ring-opening polymerization introduces batch-to-batch variation. The certificate also reports residual lactide and glycolide monomers, tin catalyst residue, water content, and storage conditions. These variables are not cosmetic; residual monomers can plasticize the matrix and accelerate initial release, while tin residues are controlled under elemental impurity risk assessments aligned with ICH Q3D. Moisture limits protect against hydrolytic degradation during warehousing and before processing. For parenteral and implantable products, the converter should verify that the lot-specific certificate of analysis falls within the intended design space and that the final device passes pharmacopoeial endotoxin limits such as Ph.Eur. 2.6.14 or USP <85>.

Solvent selection and solution viscosity exert primary control over downstream particle size in emulsion-based manufacturing. Dichloromethane and chloroform dissolve RG 756 S rapidly; acetone and ethyl acetate are possible alternatives but typically require higher solvent loadings because the high-molecular-mass fraction increases solution viscosity. At 10% w/w in dichloromethane, the solution is significantly more viscous than an equivalent concentration of a lower-IV PLGA; positive-displacement pumping is used instead of peristaltic pumping to reduce pulsation-induced droplet bimodality. In-line filtration of the organic phase through 10 µm or larger pore-size elements is common because sub-micron filters are blocked by high-molecular-mass polymer coils. Batch-to-batch variation in molecular weight distribution will shift solution viscosity even within the specified IV range, so lot qualification by rotational rheometry or capillary viscometry is recommended before scaling a solvent-based process.

What process windows govern solvent-based microsphere formation with RG 756 S?

Oil-in-water solvent extraction remains the most common conversion route. The organic phase is dispersed into an aqueous continuous phase containing 0.5–2.0% w/v poly(vinyl alcohol) at 4–10°C. Rotor-stator homogenization at tip speeds between 8 m/s and 15 m/s typically yields median droplet diameters in the 20–50 µm range; the exact droplet size depends on rotor-stator geometry, organic-phase viscosity, and continuous-phase stabilizer concentration. Droplet hardening is driven by dichloromethane extraction into the aqueous phase. Extraction vessels are maintained at 4°C for 2–4 h to limit coalescence, after which vacuum distillation or nitrogen stripping removes residual solvent. The final drug product must meet the ICH Q3C Class 2 limit for dichloromethane of 600 ppm. Scale-up from a 10 mm laboratory rotor-stator to a 50 mm pilot unit requires matching tip speed rather than impeller speed; energy dissipation rate and total shear history differ, so laser diffraction particle size analysis is required to confirm the droplet distribution. Published data for this specific configuration are otherwise limited because droplet size is determined more by emulsification equipment than by the polymer grade alone.

Lyophilization of microspheres prepared from RG 756 S can be more demanding than lyophilization of lower-molecular-weight grades because the higher solution viscosity requires larger primary droplets to maintain acceptable atomization pressure, and residual solvent must be reduced before freeze-drying. In-process controls include Karl Fischer moisture analysis, headspace gas chromatography for dichloromethane, and scanning electron microscopy of the microsphere surface. If the surface is porous, the initial release phase can accelerate even though the bulk polymer degrades slowly; therefore, surface morphology rather than particle size alone should be used to release batches. A primary drying shelf temperature below the glass transition of the formulation is used to prevent collapse; for RG 756 S, the polymer Tg of 45–50°C permits primary drying at -20°C or below, but the formulation Tg may be lower after organic solvent exposure.

Degradation-rate differences between RG 756 S and other Resomer grades arise from comonomer ratio, molecular mass, and end-group chemistry. A 50:50 PLGA hydrates faster and begins mass loss earlier in phosphate-buffered saline at 37°C because the higher glycolide content increases susceptibility to hydrolytic attack; a 75:25 PLGA of equivalent molecular mass hydrates more slowly and maintains matrix integrity longer. The 75:25 PLGA remains amorphous, which avoids crystalline regions that can cause non-uniform erosion. Compared with lower-IV 75:25 grades, RG 756 S extends release by increasing polymer network density and reducing the rate of water penetration; however, the higher viscosity reduces the maximum practical polymer concentration in solvent-based processes. Compared with acid-terminated 75:25 PLGA of similar molecular mass, the ester-terminated grade reduces the number of free carboxylic acid end groups available for autocatalytic hydrolysis, which can reduce the acid-burst effect and delay the onset of bulk degradation. Published data for exact release durations in a given formulation are limited because drug-polymer interactions, drug loading, particle size, and sterilization history all shift release kinetics.

When ester-terminated 75:25 PLGA replaces lower-viscosity PLGAs in long-acting injectables

Reformulation from a lower-molecular-weight 50:50 PLGA to RG 756 S is not a direct polymer substitution. The 75:25 grade with an inherent viscosity of 0.71–1.0 dL/g requires a lower organic-phase solids loading or a higher shear rate to maintain the same microsphere diameter. In non-aqueous in situ forming depot systems, higher molecular weight increases solution viscosity and can delay solvent exchange after injection, which prolongs the solidification front and may alter burst release. The grade is appropriate for release intervals of months rather than weeks; however, no release profile can be transferred from another PLGA grade without a discriminating dissolution method. A comparative formulation study should include molecular weight distribution by gel permeation chromatography, residual monomer content by gas chromatography, and in vitro release testing in a medium selected to detect differences in erosion lag time.

Melt processing of RG 756 S is constrained by the 45–50°C glass transition and the thermal sensitivity of PLGA. If hot-melt extrusion is used for implants, pre-drying at 25–30°C under vacuum for 24–48 h reduces hydrolytic chain scission; extruder zones are typically held between 120°C and 150°C with residence times below 5 min. Co-rotating twin-screw extruders with L/D ratios from 20:1 to 40:1 provide sufficient residence time distribution control, but screw designs with high kneading-block intensity can generate shear heating that triggers local molecular-weight loss. Torque should be monitored because a sudden torque rise indicates inadequate plasticization or insufficient pre-drying. Published data for this specific configuration are limited; small-scale thermal degradation studies by differential scanning calorimetry and thermogravimetric analysis are recommended before scaling.

Terminal sterilization of RG 756 S-containing implants and microspheres requires dose mapping and molecular-weight verification. Gamma irradiation at 25–40 kGy in accordance with ISO 11137-1 reduces PLGA molecular weight through chain scission; the magnitude is formulation-dependent and must be quantified by gel permeation chromatography and inherent viscosity after irradiation. Moisture accelerates radiation-induced chain scission, so terminal sterilization should be performed under controlled residual moisture, typically below 0.5%. Ethylene oxide sterilization is limited by residual ethylene oxide and ethylene chlorohydrin compliance with ISO 10993-7; aeration must be extended because PLGA absorbs gases. The polymer is not a finished pharmaceutical component; it is supplied as a drug delivery grade starting material. Final devices must be evaluated for endotoxins according to Ph.Eur. 2.6.14 or USP <85>, and the finished product must meet ICH Q3C residual solvent, ICH Q3D elemental impurity, and ISO 10993-1 biological evaluation requirements appropriate to the route and duration of administration.